Printer Friendly

ARES-SERONO ANNOUNCES AGREEMENT ON R-BETA INTERFERON PATENTS WITH BIOGEN

 NORWELL, Mass., and GENEVA, Jan. 11 /PRNewswire/ -- The Ares-Serono Group today announced an agreement with Biogen, Inc. (NASDAQ: BGEN) by which an Ares-Serono company, Ares Trading S.A., transferred certain rights under patents on the DNA coding for recombinant beta interferon to Biogen, Inc., while fully maintaining Ares-Serono's own rights to manufacture and market recombinant beta interferon. Financial terms of the agreement were not disclosed.
 "The agreement with Biogen will diversify Ares-Serono's position in the recombinant beta interferon market through enhanced financial participation in that market," added Fabio Bertarelli, chief executive officer of The Ares-Serono Group.
 Ares-Serono already markets a natural beta interferon and its recombinant beta interferon is currently in Phase II/III clinical trials for several immunological and oncological indications, including Phase III trials for multiple sclerosis. The company's recombinant beta interferon is already registered in Italy.
 The Ares-Serono Group is a leading Swiss developer and marketer of pharmaceutical and diagnostic products with executive headquarters in Geneva, Switzerland. The Group operates subsidiaries and production facilities in more than 20 countries. Shares of Ares-Serono S.A., the parent company of the Group, are traded on the Swiss stock exchanges.
 -0- 1/11/94
 /CONTACT: Gina Cella of Ares-Serono, 617-982-9000/
 (BGEN)


CO: Ares-Serono Group; Biogen, Inc.; Ares Trading S.A. ST: Massachusetts IN: MTC SU:

DJ-JL -- NE010 -- 1103 01/11/94 15:57 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:224
Previous Article:RAYTHEON ENGINEERS & CONSTRUCTORS PERFORMS RUSSIAN POWER PLANT STUDY
Next Article:COURT APPROVES PROPOSED TRIARC SETTLEMENT
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters